Updated NICE technology appraisal for dapagliflozin with insulin for treating type 1 diabetes (TA597)

The measures of assessing haemoglobin A1c (HbA1c) in the recommendations have been changed to reflect those commonly used in the NHS. Other minor changes have been made to the recommendations to align them with dapagliflozin's expected clinical use.


National Institute for Health and Care Excellence